Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Geovax LabsGOVX -0.34%26 EV-to-OCF is -0.08 as of Sep. 10, 2026. GuruFocus rates GOVX with a GF Score™ of 26/100. The stock has 1 warning sign investors should review. Among 1,404 Biotechnology companies, Geovax Labs ranks worse than 72.72% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Geovax Labs's Enterprise Value is $1.43 Mil.
Geovax Labs's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-18.37 Mil. Therefore, Geovax Labs's EV-to-OCF for today is -0.08.
The historical rank and industry rank for Geovax Labs's EV-to-OCF or its related term are showing as below:
GOVX'
s EV-to-OCF Range Over the Past 10 Years
Min: -9.98 Med: -0.13 Max: 6.24
Current: -0.08
During the past 13 years, the highest EV-to-OCF of Geovax Labs was 6.24. The lowest was -9.98. And the median was -0.13.
GOVX's EV-to-OCF is ranked worse than 72.72% of 1404
companies
in the Biotechnology industry
Industry Median: -3.45
vs GOVX: -0.08
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Geovax Labs's PE Ratio (TTM) for today is calculated as:
Geovax Labs's share price for today is $0.4672.
Geovax Labs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.891.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Geovax Labs EV-to-OCF Related Terms
Geovax Labs EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Geovax Labs's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Geovax Labs's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Geovax Labs EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Geovax Labs's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Geovax Labs's EV-to-OCF falls into.
Geovax Labs's current Enterprise Value is $1.43 Mil.
Geovax Labs's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-18.37 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Geovax Labs (GOVX) has a EV-to-OCF of -0.08 as of Sep. 10, 2026. According to the industry distribution chart, Geovax Labs ranks #1021 out of 1404 companies in the Biotechnology industry, placing it in the top 72.7%.
Is Geovax Labs' EV-to-OCF too high?
Geovax Labs' current EV-to-OCF is -0.08. Based on the distribution chart, Geovax Labs ranks #1021 out of 1404 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Geovax Labs has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Geovax Labs' EV-to-OCF compare to VIVS and SPRC?
According to the Biotechnology industry distribution chart, Geovax Labs ranks #1021 out of 1404 companies for EV-to-OCF. This places Geovax Labs in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Geovax Labs's current EV-to-OCF is -0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Geovax Labs stock overvalued right now?
Geovax Labs (GOVX) has a current EV-to-OCF of -0.08. The current EV-to-OCF is -0.08. Geovax Labs' overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Geovax Labs (GOVX), the current EV-to-OCF is -0.08 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
26GF Score
Get the complete analysis for GOVX
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GOVX has been successfully added to your 
